GH Research (NASDAQ:GHRS) Trading 1.4% Higher – Time to Buy?

GH Research PLC (NASDAQ:GHRS)’s share price shot up 1.4% during mid-day trading on Monday . The company traded as high as $9.72 and last traded at $9.40. 10,151 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 79,479 shares. The stock had previously closed at $9.27.

Wall Street Analyst Weigh In

Several brokerages recently commented on GHRS. Canaccord Genuity Group cut their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Wednesday, November 20th. Finally, JMP Securities reiterated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Stock Up 2.0 %

The stock’s 50-day moving average price is $7.95 and its 200 day moving average price is $10.24. The firm has a market capitalization of $482.84 million, a price-to-earnings ratio of -11.39 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. On average, sell-side analysts anticipate that GH Research PLC will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its position in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).